Recruiting × OTHER × Squamous Cell Carcinoma of Head and Neck × Clear all Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
Phase 3 Recruiting
370 enrolled
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Phase 1 Recruiting
11 enrolled
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 Recruiting
54 enrolled
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
40 enrolled
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
Phase 1 Recruiting
22 enrolled
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Phase 2 Recruiting
120 enrolled
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
92 enrolled
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
Phase 1/2 Recruiting
40 enrolled
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
Phase 2 Recruiting
30 enrolled
WOLF
Phase 2 Recruiting
87 enrolled
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Phase 2 Recruiting
100 enrolled
HOPE
Phase 3 Recruiting
228 enrolled
GALENOS 2
Phase NA Recruiting
52 enrolled
GALENOS 1
Recruiting
110 enrolled
BIOMATCH
Recruiting
300 enrolled
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Phase 2/3 Recruiting
686 enrolled
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Phase 2 Recruiting
98 enrolled
DART-HN
Phase NA Recruiting
40 enrolled
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Phase 1 Recruiting
40 enrolled
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Phase 2 Recruiting
32 enrolled
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Phase 2 Recruiting
32 enrolled
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Phase 2 Recruiting
45 enrolled
POST-BIO
Phase 2 Recruiting
45 enrolled
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Phase 2 Recruiting
38 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
The Role of Circulating Tumour DNA in Head and Neck Cancer
Recruiting
250 enrolled
DIREKHT2
Phase 2/3 Recruiting
508 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
Phase 1 Recruiting
24 enrolled
DoIT_Neck
Recruiting
250 enrolled
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
9 enrolled
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Phase 1 Recruiting
30 enrolled
HN-Quest
Phase NA Recruiting
173 enrolled
HN-BIO
Phase NA Recruiting
60 enrolled
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Phase 2 Recruiting
30 enrolled
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
Phase 1 Recruiting
30 enrolled
HN-Bio 02
Phase NA Recruiting
40 enrolled
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Phase 1 Recruiting
40 enrolled
PEMBRO-PET
Recruiting
25 enrolled
KIEO
Phase 2 Recruiting
30 enrolled
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Phase 2 Recruiting
27 enrolled
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Phase 2 Recruiting
29 enrolled
RePaIr-HN
Phase 3 Recruiting
214 enrolled
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Phase 2 Recruiting
12 enrolled
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Phase 2 Recruiting
25 enrolled
RAD RAPTORS
Phase 2 Recruiting
42 enrolled
HOUSTON
Phase NA Recruiting
400 enrolled
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
Recruiting
30 enrolled
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Phase 2 Recruiting
21 enrolled
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
Phase 2 Recruiting
108 enrolled